Also known as: LIXTE Biotechnology Holdings
Lixte Biotechnology Holdings is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and the commercialization of cancer therapies. The company uses biomarker technology to identify enzyme targets associated with cancer and other serious diseases.
LIXTE Biotechnology Holdings appointed Sidney Braun as CEO of its Liora Technologies Europe Ltd. subsidiary to lead advancement of the LiGHT System proton therapy platform following the company's November 2025 acquisition of Liora's assets.
LIXTE Biotechnology Holdings appointed Sidney Braun as CEO of its Liora Technologies Europe Ltd. subsidiary on February 18, 2026. Braun brings over 20 years of healthcare experience and facilitated LIXTE's November 2025 acquisition of Liora's assets.
LIXTE Biotechnology Holdings is developing LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness across multiple cancer types, with proof-of-concept trials underway.
